OFIX

SEC source: 0001209191-22-024287 · doc4.xml · nonDerivative · entry 1

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,679

F1 · shares: Represents time-based vesting restricted stock units that vest in 25% increments on the first, second, third and forth anniversaries of the grant date, April 11, 2022.

SEC source: 0001209191-22-023342 · doc4.xml · nonDerivative · entry 4

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,742

SEC source: 0001209191-22-023337 · doc4.xml · nonDerivative · entry 4

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Develop. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,576

SEC source: 0001209191-22-023347 · doc4.xml · nonDerivative · entry 1

Gonsalves Paul · CIK 0001824319 · President, Global Orthopedics

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,716

SEC source: 0001209191-22-023345 · doc4.xml · nonDerivative · entry 2

Kenny Kevin J. · CIK 0001520400 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,688

SEC source: 0001209191-22-023345 · doc4.xml · nonDerivative · entry 1

Kenny Kevin J. · CIK 0001520400 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,441

SEC source: 0001209191-22-023342 · doc4.xml · nonDerivative · entry 3

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,105

SEC source: 0001209191-22-023342 · doc4.xml · nonDerivative · entry 2

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,490

SEC source: 0001209191-22-023342 · doc4.xml · nonDerivative · entry 1

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,807

SEC source: 0001209191-22-023339 · doc4.xml · nonDerivative · entry 2

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 188,839

SEC source: 0001209191-22-023339 · doc4.xml · nonDerivative · entry 1

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 190,880

SEC source: 0001209191-22-023337 · doc4.xml · nonDerivative · entry 3

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Develop. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,910

SEC source: 0001209191-22-023337 · doc4.xml · nonDerivative · entry 2

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Develop. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,112

SEC source: 0001209191-22-023337 · doc4.xml · nonDerivative · entry 1

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Develop. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,941

SEC source: 0001209191-22-006838 · doc4.xml · derivative · entry 2

Gonsalves Paul · CIK 0001824319 · President, Global Orthopedics

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,836

Underlying: Common Stock · 9,836 shares

Expires not disclosed

F2 · derivative.exercise_date: Represents performance-based vesting restricted stock units ("PSUs") that will settle as common stock on a one-for-one basis. Under the terms of the grant, the PSUs may vest based upon achieved product revenues for the 2023 fiscal year (the "Product Revenue Vesting Percentage"), as modified by a total shareholder return ("TSR") modifier (the "TSR Modifier"). The amount in the table above represents the target number of PSUs granted. The performance period of the grant is 2/1/22-1/31/25. The Product Revenue Vesting Percentage can be achieved within a range of 50% to 200% of target, based upon the level of recognized revenues. If the Product Revenue Vesting Percentage is achieved at or above the threshold level, it shall be multiplied by the TSR Modifier (ranging from 0.75 to 1.25), which shall be determined based on the Company's relative TSR during the performance period as compared to a specified peer group.

F2 · derivative.expiration_date: Represents performance-based vesting restricted stock units ("PSUs") that will settle as common stock on a one-for-one basis. Under the terms of the grant, the PSUs may vest based upon achieved product revenues for the 2023 fiscal year (the "Product Revenue Vesting Percentage"), as modified by a total shareholder return ("TSR") modifier (the "TSR Modifier"). The amount in the table above represents the target number of PSUs granted. The performance period of the grant is 2/1/22-1/31/25. The Product Revenue Vesting Percentage can be achieved within a range of 50% to 200% of target, based upon the level of recognized revenues. If the Product Revenue Vesting Percentage is achieved at or above the threshold level, it shall be multiplied by the TSR Modifier (ranging from 0.75 to 1.25), which shall be determined based on the Company's relative TSR during the performance period as compared to a specified peer group.

SEC source: 0001209191-22-006838 · doc4.xml · nonDerivative · entry 1

Gonsalves Paul · CIK 0001824319 · President, Global Orthopedics

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,403

F1 · shares: Represents time-based vesting restricted stock units that vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, February 1, 2022.

SEC source: 0001209191-22-006837 · doc4.xml · derivative · entry 2

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Develop. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,492

Underlying: Common Stock · 20,492 shares

Expires not disclosed

F2 · derivative.exercise_date: Represents performance-based vesting restricted stock units ("PSUs") that will settle as common stock on a one-for-one basis. Under the terms of the grant, the PSUs may vest based upon achieved product revenues for the 2023 fiscal year (the "Product Revenue Vesting Percentage"), as modified by a total shareholder return ("TSR") modifier (the "TSR Modifier"). The amount in the table above represents the target number of PSUs granted. The performance period of the grant is 2/1/22-1/31/25. The Product Revenue Vesting Percentage can be achieved within a range of 50% to 200% of target, based upon the level of recognized revenues. If the Product Revenue Vesting Percentage is achieved at or above the threshold level, it shall be multiplied by the TSR Modifier (ranging from 0.75 to 1.25), which shall be determined based on the Company's relative TSR during the performance period as compared to a specified peer group.

F2 · derivative.expiration_date: Represents performance-based vesting restricted stock units ("PSUs") that will settle as common stock on a one-for-one basis. Under the terms of the grant, the PSUs may vest based upon achieved product revenues for the 2023 fiscal year (the "Product Revenue Vesting Percentage"), as modified by a total shareholder return ("TSR") modifier (the "TSR Modifier"). The amount in the table above represents the target number of PSUs granted. The performance period of the grant is 2/1/22-1/31/25. The Product Revenue Vesting Percentage can be achieved within a range of 50% to 200% of target, based upon the level of recognized revenues. If the Product Revenue Vesting Percentage is achieved at or above the threshold level, it shall be multiplied by the TSR Modifier (ranging from 0.75 to 1.25), which shall be determined based on the Company's relative TSR during the performance period as compared to a specified peer group.

SEC source: 0001209191-22-006837 · doc4.xml · nonDerivative · entry 1

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Develop. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,295

F1 · shares: Represents time-based vesting restricted stock units that vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, February 1, 2022.

SEC source: 0001209191-22-006835 · doc4.xml · derivative · entry 2

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,967

Underlying: Common Stock · 81,967 shares

Expires not disclosed

F2 · derivative.exercise_date: Represents performance-based vesting restricted stock units ("PSUs") that will settle as common stock on a one-for-one basis. Under the terms of the grant, the PSUs may vest based upon achieved product revenues for the 2023 fiscal year (the "Product Revenue Vesting Percentage"), as modified by a total shareholder return ("TSR") modifier (the "TSR Modifier"). The amount in the table above represents the target number of PSUs granted. The performance period of the grant is 2/1/22-1/31/25. The Product Revenue Vesting Percentage can be achieved within a range of 50% to 200% of target, based upon the level of recognized revenues. If the Product Revenue Vesting Percentage is achieved at or above the threshold level, it shall be multiplied by the TSR Modifier (ranging from 0.75 to 1.25), which shall be determined based on the Company's relative TSR during the performance period as compared to a specified peer group.

F2 · derivative.expiration_date: Represents performance-based vesting restricted stock units ("PSUs") that will settle as common stock on a one-for-one basis. Under the terms of the grant, the PSUs may vest based upon achieved product revenues for the 2023 fiscal year (the "Product Revenue Vesting Percentage"), as modified by a total shareholder return ("TSR") modifier (the "TSR Modifier"). The amount in the table above represents the target number of PSUs granted. The performance period of the grant is 2/1/22-1/31/25. The Product Revenue Vesting Percentage can be achieved within a range of 50% to 200% of target, based upon the level of recognized revenues. If the Product Revenue Vesting Percentage is achieved at or above the threshold level, it shall be multiplied by the TSR Modifier (ranging from 0.75 to 1.25), which shall be determined based on the Company's relative TSR during the performance period as compared to a specified peer group.

SEC source: 0001209191-22-006835 · doc4.xml · nonDerivative · entry 1

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 194,779

F1 · shares: Represents time-based vesting restricted stock units that vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, February 1, 2022.

SEC source: 0001209191-22-006833 · doc4.xml · derivative · entry 2

Kenny Kevin J. · CIK 0001520400 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,492

Underlying: Common Stock · 20,492 shares

Expires not disclosed

F2 · derivative.exercise_date: Represents performance-based vesting restricted stock units ("PSUs") that will settle as common stock on a one-for-one basis. Under the terms of the grant, the PSUs may vest based upon achieved product revenues for the 2023 fiscal year (the "Product Revenue Vesting Percentage"), as modified by a total shareholder return ("TSR") modifier (the "TSR Modifier"). The amount in the table above represents the target number of PSUs granted. The performance period of the grant is 2/1/22-1/31/25. The Product Revenue Vesting Percentage can be achieved within a range of 50% to 200% of target, based upon the level of recognized revenues. If the Product Revenue Vesting Percentage is achieved at or above the threshold level, it shall be multiplied by the TSR Modifier (ranging from 0.75 to 1.25), which shall be determined based on the Company's relative TSR during the performance period as compared to a specified peer group.

F2 · derivative.expiration_date: Represents performance-based vesting restricted stock units ("PSUs") that will settle as common stock on a one-for-one basis. Under the terms of the grant, the PSUs may vest based upon achieved product revenues for the 2023 fiscal year (the "Product Revenue Vesting Percentage"), as modified by a total shareholder return ("TSR") modifier (the "TSR Modifier"). The amount in the table above represents the target number of PSUs granted. The performance period of the grant is 2/1/22-1/31/25. The Product Revenue Vesting Percentage can be achieved within a range of 50% to 200% of target, based upon the level of recognized revenues. If the Product Revenue Vesting Percentage is achieved at or above the threshold level, it shall be multiplied by the TSR Modifier (ranging from 0.75 to 1.25), which shall be determined based on the Company's relative TSR during the performance period as compared to a specified peer group.

SEC source: 0001209191-22-006833 · doc4.xml · nonDerivative · entry 1

Kenny Kevin J. · CIK 0001520400 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,643

F1 · shares: Represents time-based vesting restricted stock units that vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, February 1, 2022.

SEC source: 0001209191-22-006829 · doc4.xml · derivative · entry 2

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,131

Underlying: Common Stock · 22,131 shares

Expires not disclosed

F2 · derivative.exercise_date: Represents performance-based vesting restricted stock units ("PSUs") that will settle as common stock on a one-for-one basis. Under the terms of the grant, the PSUs may vest based upon achieved product revenues for the 2023 fiscal year (the "Product Revenue Vesting Percentage"), as modified by a total shareholder return ("TSR") modifier (the "TSR Modifier"). The amount in the table above represents the target number of PSUs granted. The performance period of the grant is 2/1/22-1/31/25. The Product Revenue Vesting Percentage can be achieved within a range of 50% to 200% of target, based upon the level of recognized revenues. If the Product Revenue Vesting Percentage is achieved at or above the threshold level, it shall be multiplied by the TSR Modifier (ranging from 0.75 to 1.25), which shall be determined based on the Company's relative TSR during the performance period as compared to a specified peer group.

F2 · derivative.expiration_date: Represents performance-based vesting restricted stock units ("PSUs") that will settle as common stock on a one-for-one basis. Under the terms of the grant, the PSUs may vest based upon achieved product revenues for the 2023 fiscal year (the "Product Revenue Vesting Percentage"), as modified by a total shareholder return ("TSR") modifier (the "TSR Modifier"). The amount in the table above represents the target number of PSUs granted. The performance period of the grant is 2/1/22-1/31/25. The Product Revenue Vesting Percentage can be achieved within a range of 50% to 200% of target, based upon the level of recognized revenues. If the Product Revenue Vesting Percentage is achieved at or above the threshold level, it shall be multiplied by the TSR Modifier (ranging from 0.75 to 1.25), which shall be determined based on the Company's relative TSR during the performance period as compared to a specified peer group.

SEC source: 0001209191-22-006829 · doc4.xml · nonDerivative · entry 1

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,674

F1 · shares: Represents time-based vesting restricted stock units that vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, February 1, 2022.

SEC source: 0001209191-21-069810 · doc4.xml · derivative · entry 1

West Thomas A. · CIK 0001620705 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,450

Underlying: Common Stock · 29,450 shares

Expires 2031-12-13

F1 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, December 13, 2021.

SEC source: 0001209191-21-068393 · doc4.xml · nonDerivative · entry 1

Kenny Kevin J. · CIK 0001520400 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,151

SEC source: 0001209191-21-066189 · doc4.xml · nonDerivative · entry 1

Paolucci Michael E · CIK 0001599463 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,141

SEC source: 0001209191-21-065776 · doc4.xml · nonDerivative · entry 1

BURZIK CATHERINE M · CIK 0001261141 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,947

SEC source: 0001209191-21-065779 · doc4.xml · nonDerivative · entry 1

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,543

SEC source: 0001209191-21-065552 · doc4.xml · nonDerivative · entry 1

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,812

SEC source: 0001209191-21-065545 · doc4.xml · nonDerivative · entry 1

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Develop. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,803

SEC source: 0001209191-21-062275 · doc4.xml · nonDerivative · entry 1

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,903

SEC source: 0001209191-21-058107 · doc4.xml · derivative · entry 1

BURRIS WAYNE · CIK 0001885420 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,184

Underlying: Common Stock · 22,184 shares

Expires 2031-09-22

F1 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, September 22, 2021.

SEC source: 0001209191-21-055721 · doc4.xml · nonDerivative · entry 1

Gonsalves Paul · CIK 0001824319 · President, Global Orthopedics

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,567

SEC source: 0001209191-21-055054 · doc4.xml · nonDerivative · entry 1

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Develop. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,953

SEC source: 0001209191-21-050298 · doc4.xml · nonDerivative · entry 1

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,272

SEC source: 0001209191-21-045860 · doc4.xml · nonDerivative · entry 1

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Develop. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,318

SEC source: 0001209191-21-045855 · doc4.xml · nonDerivative · entry 1

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,370

SEC source: 0001209191-21-042755 · doc4.xml · derivative · entry 2

BURZIK CATHERINE M · CIK 0001261141 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,361

Underlying: Common Stock · 21,361 shares

Expires 2031-06-21

F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, June 21, 2021.

SEC source: 0001209191-21-042755 · doc4.xml · nonDerivative · entry 1

BURZIK CATHERINE M · CIK 0001261141 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,976

F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The award vests in full on the first anniversary of the grant date, June 21, 2021.

SEC source: 0001209191-21-042751 · doc4.xml · nonDerivative · entry 1

SICARD JOHN · CIK 0001734027 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,232

F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The award vests in full on the first anniversary of the grant date, June 21, 2021.

SEC source: 0001209191-21-042749 · doc4.xml · nonDerivative · entry 1

Lukianov Alexis V · CIK 0001289410 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,027

F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The award vests in full on the first anniversary of the grant date, June 21, 2021.

SEC source: 0001209191-21-042747 · doc4.xml · nonDerivative · entry 1

MARKS LILLY · CIK 0001645735 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,573

F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The award vests in full on the first anniversary of the grant date, June 21, 2021.

SEC source: 0001209191-21-042743 · doc4.xml · nonDerivative · entry 1

Paolucci Michael E · CIK 0001599463 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,814

F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The award vests in full on the first anniversary of the grant date, June 21, 2021.

SEC source: 0001209191-21-042740 · doc4.xml · nonDerivative · entry 1

Hinrichs James F. · CIK 0001506974 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,594

F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The award vests in full on the first anniversary of the grant date, June 21, 2021.

SEC source: 0001209191-21-042737 · doc4.xml · nonDerivative · entry 1

Hannon Jason · CIK 0001330401 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,431

F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The award vests in full on the first anniversary of the grant date, June 21, 2021.

SEC source: 0001209191-21-025417 · doc4.xml · nonDerivative · entry 5

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,478

SEC source: 0001209191-21-025412 · doc4.xml · nonDerivative · entry 5

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Develop. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,217

SEC source: 0001209191-21-025424 · doc4.xml · derivative · entry 2

Gonsalves Paul · CIK 0001824319 · President, Global Extremities

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,988

Underlying: Common Stock · 6,988 shares

Expires not disclosed

F2 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as April 1, 2021 to April 1, 2024. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P 600 Health Care Equipment & Services Industry Group Index (S6HCES) as of April 1, 2021, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

F2 · derivative.expiration_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as April 1, 2021 to April 1, 2024. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P 600 Health Care Equipment & Services Industry Group Index (S6HCES) as of April 1, 2021, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

SEC source: 0001209191-21-025424 · doc4.xml · nonDerivative · entry 1

Gonsalves Paul · CIK 0001824319 · President, Global Extremities

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,612

F1 · shares: Represents time-based vesting restricted stock units that vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 1, 2021.